science

Vilobelimab

Vilobelimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Vilobelimab rather than just read about it. In short: Vilobelimab, sold under the brand name Gohibic, is a monoclonal antibody that is used for the treatment of COVID-19. It is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma.

Key takeaways

Vilobelimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Vilobelimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Vilobelimab from memory before moving on to harder problems.

Reference excerpt

Vilobelimab, sold under the brand name Gohibic, is a monoclonal antibody that is used for the treatment of COVID-19. It is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma. The most common adverse reactions include pneumonia, sepsis, delirium, pulmonary embolism, hypertension, pneumothorax, deep vein thrombosis, herpes simplex, enterococcal infection, bronchopulmonary aspergillosis, hepatic enzyme increased, urinary tract infection, hypoxia, thrombocytopenia, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash. Vilobelimab is a recombinant chimeric monoclonal IgG4 antibody that specifically binds to the soluble human complement split product C5a after cleavage from C5 to block its interaction with the C5a receptor, both of which are components of the complement system thought to contribute to inflammation and worsening of COVID-19. Vilobelimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in April 2023. Vilobelimab was authorized for medical use in the European Union in January 2025.

Medical uses In the US, vilobelimab is authorized via an emergency use authorization for use in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (artificial life support). Vilobelimab is not approved by the US Food and Drug Administration (FDA) for any indication, including for the treatment of COVID-19. In the EU, vilobelimab is indicated for the treatment of adults with SARS-CoV-2 induced acute respiratory distress syndrome who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (with or without extracorporeal membrane oxygenation).

History The clinical trial supporting the authorization showed that participants treated with vilobelimab had a lower risk of death by day 28 and day 60 of treatment compared to placebo.

Society and culture

Legal status In November 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Gohibic intended for the treatment of adults with SARS‑CoV2‑induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids. The applicant for this medicinal product is InflaRx GmbH. Vilobelimab was authorized for medical use in the European Union in January 2025.

Names Vilobelimab is the international nonproprietary name.

References

Further reading Vlaar AP, Witzenrath M, van Paassen P, Heunks LM, Mourvillier B, de Bruin S, et al. (December 2022). "Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial". The Lancet. Respiratory Medicine. 10 (12): 1137–1146. doi:10.1016/S2213-2600(22)00297-1. PMC 9451499. PMID 36087611.{{cite journal}}: CS1 maint: overridden setting (link)

External links Clinical trial number NCT04333420 for "Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Vilobelimab

Start with the simplest possible case. Write down what Vilobelimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Vilobelimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Vilobelimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Vilobelimab

In research: Vilobelimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Vilobelimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Vilobelimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antiviral drugs, COVID-19 drug development, Experimental antiviral drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Vilobelimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Vilobelimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Vilobelimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Vilobelimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Vilobelimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Vilobelimab in simple terms?

Vilobelimab, sold under the brand name Gohibic, is a monoclonal antibody that is used for the treatment of COVID-19. It is a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma.

Why does Vilobelimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Vilobelimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Vilobelimab.